Wave Life Sciences Shares Plunge as Data for High Dose of Obesity Drug ...

Stock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data Disappoints

Wave Life Sciences (NASDAQ:WVE), developer of RNA medicines for rare genetic diseases, closed Thursday at $6.20, down 49.59% for the session. The stock sank after disappointing higher-dose WVE-007 obesity data underperformed the lower dose. Trading volume reached 49.9 million shares, coming in about 1,153% above its three-month average of 4 million shares. Wave Life Sciences IPO'd in 2015 and has fallen 61% since going public.How the markets mov…

Wave's stock wavers on obesity drug data

Wave Life Sciences has said new clinical trial results with its non-incretin therapy for weight loss are positive – but investors don't seem to agree

Why Is Wave Life Sciences Stock Falling After Weight Loss Study Data? - WAVE Life Sciences (NASDAQ:WVE)

Wave Life Sciences stock drops after INLIGHT Phase 1 data. WVE-007 shows fat reduction, lean mass stability, and biomarker suppression. Importance Rank:  1

Wave Life Sciences (WVE) Stock Plunges as Obesity Drug Falls Short on ...

Wave Life Sciences shares plunge as data for high dose of obesity drug ...

Wave Life Sciences plunges after obesity data (WVE:NASDAQ)

Wave Life Sciences (WVE) stock plunges as the company interim data from an early-stage trial for WVE-007, its RNA-based obesity medicine. Read more here.